Dogwood Therapeutics (DWTX)

• Market cap: $116M
• 1 day: -7.38%
• 5 days: -19.79%
• 1 month: -38.74%
• 3 months: -49.48%
• 6 months: -18.45%
• Year to date: 54.98%
• 1 year: 36.49%
• 5 years: -98.09%
• 10 years: -99.07%
• Sector: Healthcare
• Industry: Biotechnology

About: Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Employees: 12